News coverage about Krystal Biotech (NASDAQ:KRYS) has trended somewhat positive on Tuesday, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Krystal Biotech earned a news impact score of 0.03 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.6410684391293 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Krystal Biotech, Inc. (KRYS) Announces Quarterly Earnings Results, Misses Estimates By $0.52 EPS (americanbankingnews.com)
- BRIEF-Krystal Biotech reports qtrly loss per share $1.26 (reuters.com)
- Krystal Biotech Reports that KB103 Received Clearance From RAC Review and Announces Third Quarter 2017 Financial Results (finance.yahoo.com)
- Krystal Biotech (KRYS) Announces KB103 Granted Orphan Drug Designation by FDA to Treat Patients With DEB (streetinsider.com)
- Krystal Biotech’s KB103 Granted Orphan Drug Designation by the FDA to Treat Patients With Dystrophic Epidermolysis Bullosa (finance.yahoo.com)
Separately, Ladenburg Thalmann Financial Services initiated coverage on shares of Krystal Biotech in a report on Wednesday, October 18th. They issued a “buy” rating and a $23.00 price target on the stock.
Shares of Krystal Biotech (KRYS) traded up $0.38 on Tuesday, hitting $10.56. 46,600 shares of the company traded hands, compared to its average volume of 32,297. Krystal Biotech has a fifty-two week low of $9.01 and a fifty-two week high of $11.98.
Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 13th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.52). research analysts forecast that Krystal Biotech will post -1.32 EPS for the current fiscal year.
In other news, Director Daniel Janney acquired 200,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, September 22nd. The shares were acquired at an average price of $10.00 per share, with a total value of $2,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Suma Krishnan acquired 100,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, September 22nd. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $1,000,000.00. Following the purchase, the chief operating officer now directly owns 1,935,249 shares of the company’s stock, valued at approximately $19,352,490. The disclosure for this purchase can be found here.
Krystal Biotech Company Profile
Krystal Biotech, Inc gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases.
Receive News & Ratings for Krystal Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.